Clinical Trial

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2017-06-22; most recent amendment 2026-06-12.
Status change: Recruiting → Active, Not Recruiting 2025-01-03
Status change: Not Yet Recruiting → Recruiting 2018-03-02
Trial Details
NCT Number NCT03198026
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators: Genentech, Inc., Pharmacyclics LLC.
Conditions Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma +11 more
Enrollment 30 participants
Start Date 2018-02-20
Primary Completion 2026-09-11 (estimated)
Study Completion 2032-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-02-19